Thrombocytopenia is recognized as a potential adverse effect in patients treated with glycoprotein IIb/IIIa inhibitors. We monitored platelet counts at baseline and at 10 minutes and at 1, 8, and 24 hours after initiation of therapy with either abciximab (n = 74) or eptifibatide (n = 26) in a series of 100 consecutive patients who underwent percutaneous coronary intervention. Thrombocytopenia (platelet count <100,000 m(3) occurred in 11 patients treated with abciximab (15%) and in none of those treated with eptifibatide. The inhibition of platelet adhesion to fibrinogen-coated material by abciximab and eptifibatide was similar, indicating that the reduction in platelet count with abciximab is unrelated to inhibition of platelet function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2003.10.041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adverse Drug Effect Profiles of Gp2b/3a Inhibitors: A Comparative Review of the Last Two Decades.
Cureus
November 2023
General Medicine, American University of Antigua College of Medicine, St John's, ATG.
ST-Elevation Myocardial Infarction and non-ST Elevation Myocardial Infarction belong to the acute coronary syndrome group of diseases. These conditions are characterized by the complete or partial blockage of one or several coronary arteries, resulting in myocardial injury or necrosis. Various medications are used in their treatment, with the most recent addition being Glycoprotein IIb/IIIa inhibitors.
View Article and Find Full Text PDFThrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000-100 000 platelets/μL), to severe (20 000 to <50 000/μL), to profound (<20 000/μL). Profound thrombocytopenia appears to occur in <1% of patients receiving their first course of therapy.
View Article and Find Full Text PDFEfficacy, Safety, and Role of Antiplatelet Drugs in the Management of Acute Coronary Syndrome: A Comprehensive Review of Literature.
Cureus
March 2023
Department of Forensic Medicine, Postgraduate Medical Institute (PGMI), Lahore, PAK.
Acute coronary syndrome (ACS) is a complex condition characterized by myocardial ischemia or infarction which can lead to significant morbidity and death. Antiplatelet drugs play a crucial role in the management of ACS and have been shown to minimize the incidence of significant adverse cardiovascular events and recurrent myocardial infarction (MI). This comprehensive literature review is intended to summarize current information on the effectiveness, safety, and function of frequently used antiplatelet medications in treating ACS.
View Article and Find Full Text PDFGlycoprotein IIb/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis.
Neuroradiol J
April 2024
Department of Neurosurgery, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Background And Aims: Thromboembolism complication is considered the most common complication associated with the treatment of endovascular. This systematic review and meta-analysis aimed to assess the studies investigating the effect of glycoprotein IIb/IIIa inhibitor agents on thromboembolic complications during endovascular aneurysm coiling.
Materials And Methods: This systematic review investigated the outcome of the use of three glycoprotein IIb/IIIa inhibitor agents (ie abciximab, tirofiban, and eptifibatide) on the thromboembolic complications during endovascular aneurysm coiling.
An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives.
High Blood Press Cardiovasc Prev
March 2023
Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania.
The glycoprotein (GP) IIb/IIIa receptor is found integrin present in platelet aggregations. GP IIb/IIIa antagonists interfere with platelet cross-linking and platelet-derived thrombus formation through the competition with fibrinogen and von Willebrand factor. Currently, three parenteral GP IIb/IIIa competitors (tirofiban, eptifibatide, and abciximab) are approved for clinical use in patients affected by percutaneous coronary interventions (PCI) in the location of acute coronary syndrome (ACS).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!